海尔生物(688139):海尔生物2025年可持续发展报告（英文版）
原标题:海尔生物:海尔生物2025年可持续发展报告（英文版） About This Report 3 Appendix ESG Performance Indicators 94 Chairman's Statement 4 Shanghai Stock Exchange Guidelines Index 96 About Haier Biomedical 5 GRI Standards Index 97 Company Profile 5 UNGC Principles Index 100 Milestones 6 Honors and Awards 7 Sustainability Governance 9 Special Feature Innovation-Led: Integrity and Shared Sharing the Future: Green Symbiosis: Global Technology Expansion, Safeguarding the Life Success: Ensuring Leading People-Centered Driving Ecological Serving Global Health: Barrier Steady Development Shared Prosperity Harmony01 02 03 04 Operational Roots: Building a 1.1 R&D and Innovation 23 2.1 Compliance Operations 34 3.1 Stimulating Individual 57 4.1 Green Products 78 Localized Service Network 17 Potential 1.2 Industry Leading 28 2.2 Sustainable Supply Chain 40 4.2 Environmental Responsibility 80 Program Leadership: Building a 3.2 Contributing to Healthy 7144 4.3 Resource Usage 1.3 R&D Achievements 30 2.3 Product Quality and Safety 83Scenario-Based Digital Ecosystem 17 Communities 1.4 Intellectual Property 34 2.4 Customer Rights and 51 4.4 Emissions Management 87 Tech Synergy: Empowering Global Protection Quality Service Cutting-Edge Research 18 4.5 Address Climate Change 90 Green Empowerment: Innovative 4.6 Biodiversity Conservation 93 Low-Carbon Solutions 19 Chairman's Statementthis innovation improves reproducibility and reduces manual Closing Remarks intervention, supporting more efficient laboratory operations, As the transformative wave of artificial intelligence sweeps enhancing workforce productivity, and enabling scalable, high- Haier Biomedical is evolving from a specialized equipment across the globe, we stand at the cusp of a historic inflection quality sample processing for research and clinical applications. manufacturer into a world-class life sciences brand with platform point. This shift extends beyond incremental tool upgrades, capabilities and a global perspective. We know that this journey Network Transformation - From "Global Sales" to "Local Integration". fundamentally redefining productivity and cognitive paradigms. has only just begun. Our localized operating networks across 18 countries represent For Haier Biomedical, with over two decades of focus in life science more than market expansion; they demonstrate the global Guided by two decades of industry insight and grounded in a instruments, it is clear that a new era, shaped by data, algorithms, applicability of our intelligent platform capabilities. In Italy, our commitment to technological excellence and the wellbeing of and automation, is rapidly unfolding. intelligent blood management system is helping improve the people and the planet, Haier Biomedical will continue to advance Amid the convergence of technological advancement and mission- efficiency of the public healthcare system. In remote regions of in partnership with scientists, industry partners, investors, and driven purpose, Haier Biomedical has further clarified its strategic Africa, solar-powered vaccine refrigerators equipped with intelligent communities worldwide. positioning. We are committed to becoming a global leader in temperature control systems are helping safeguard children's ? RKN temperature- ? "Pharmacy Management ? Delivery of the Smart Medical Community project jointly controlled container Scenario Large Model" project developed with Sangzhuzi District, Shigatse City, Tibet. received first FAA selected as a Shandong ? Jointly built Xinjiang's first design approval "Open Competition Blood Donation Care Cabin ? Two ultra-energy-saving ultra-low temperature freezers letter in Asia-Pacific. Mechanism" project. with Alar City. passed DIN testing.May March June August April July ? RAP-AT1 active ? Guizhou’s first demonstration AI vaccination clinic ? Dual-system variable frequency series ultra-low temperature ? Led the formulation of temperature-controlled launched in Guiyang. freezers obtained ACT certification. China's first national container received CAAC standard for the Medical ? Received world's first EU MDR certificate for medical low- ? The Application of Solar Direct Drive (SDD) Vaccine CTSOA certificate. Liquid Nitrogen Storage temperature storage equipment. Refrigerators selected as one of the first batch of cultivation Systems. cases of "DC100 International DC Application". ? Received the first humidity control certification certificate for medical refrigerators. ? Three industry standards led or deeply participated in by its subsidiary Qingdao HB TempCon Aviation Technology Co., ? Smart digital fully automatic cell culture workstation Ltd. were officially released: the Technical Specification for recognized as an outstanding typical case of future Aviation Temperature-Controlled Containers, the Operational industry innovation development by MIIT. Specification for Public Air Transport of Temperature- ? Participated in the formulation and release of the Controlled Cargo, and the Technical Specification for group standard Technical Specification for Deep Low- Aviation Fire-Resistant Containers. Honors and Awards Technology and Innovation Project Name Award/Honor Name Issuing Organization R&D and Industrialization of Key Equipment and Supporting Systems of Haier 2025 National "Two Major Initiatives" Project in the Biological Field National Development and Reform Biomedical Commission (NDRC) Key Technology Development and Industrialization of High-Throughput Cell 2024 Outstanding Typical Case of Future Industry Innovation Ministry of Industry and Information Automated Culture Equipment Development Technology (MIIT) National Postdoctoral Research Station National Postdoctoral Research Workstation (Excellence Award) Ministry of Human Resources and Social Security Key Technology Development and Equipment Industrialization for High-Quality Excellence Award (Highest Award) in the National Finals of the 14th Ministry of Industry and Information and High-Efficiency Cell Preparation China Innovation and Entrepreneurship Competition for Disruptive Technology (MIIT) Technology Innovation Fully Automated and Standardized High-Efficiency Cell Preparation Workstation National Disruptive Technology Innovation Competition Ministry of Science and Technology R&D and Application of Key Technologies for Constant Temperature Green and 2024 Science and Technology Progress Award of China National China National Light Industry Council Highly Reliable Refrigeration Equipment for Biomedical Safe Storage Light Industry CouncilKey Technology Development and Industrialization of Compact Automated Shandong Provincial Science and Technology Progress Award Department of Science and Biological Culture Equipment Technology of Shandong ProvinceR&D and Industrialization of Key Technologies and Series Equipment for Green 2025 Science and Technology Progress Award of Shandong Province Shandong Province Equipment Low-Temperature Storage of Biological Samples Equipment Manufacturing Association Manufacturing Association Development and Application of Flexible and Expandable Ultra-Low 2025 Science and Technology Progress Award of Shandong Province Shandong Province Medical Device Temperature Fully Automated Biological Sample Storage Technology and Series Medical Device Industry Association Industry Association Products R&D and Industrialization of Key Technologies and Series Equipment for Green 2025 Science and Technology Progress Award of Shandong Province Shandong Province Medical Device Low-Temperature Storage of Biological Samples Medical Device Industry Association Industry Association R&D and Industrialization of Key Technologies and Series Equipment for Green Qingdao Science and Technology Progress Award Qingdao Municipal Bureau of Science Low-Temperature Storage of Biological Samples and TechnologySocial Awards Award/Honor Name Organizer 2025 Wind ESG Top 100 (Small and Mid-cap) Wind Selected for S&P Global's 2025 Sustainability Yearbook (China Edition) S&P Global 2025 Evergreen Enterprise Case Selection – Sustainable Development Leader Caijing The 3rd Guoxin Cup · ESG Technology Leading Golden Bull Award China Securities Journal 2025 Hardcore Technology Innovation Case China Times Securities Star 3rd ESG New Benchmark Enterprise Securities Star 2025 JRJ Golden Intelligence Award – Outstanding Growth Enterprise JRJ.com Future 20 · 2025 A-Share Listed Company Annual Growth Enterprise Jointly initiated by China Business Network, EY (China), Xiya Asset Management, and Shanghai Jiading New City Development Co., Ltd. Haier Biomedical recognizes that the opinions of stakeholders are critical to the Company's operations and development. We consistently pay attention to the opinions and demands of internal and external stakeholders, listen to and respond to their needs through comprehensive, multi-channel communication mechanisms, and integrate their expectations into our daily management and decision-making as appropriate, with the aim of building long-term, mutually trusting partnerships that create shared value. Key Stakeholders Issues Communication Channels Governments and regulators ? Compliant operation ? Green manufacturing ? Government consultation ? Working conferences ? Information security ? Biodiversity ? Information disclosure ? Responses to inquiries ? Responsible marketing ? Corporate governance ? Topic reporting Shareholders and investors ? Corporate governance ? Anti-corruption ? Information disclosure ? Online platforms ? Compliance operation ? Investor relations ? Shareholders' meetings ? Roadshows ? Protection of intellectual ? Performance briefing ? Institutions’ research meetings properties Customers ? Customers’ rights and interests ? Quality service ? Product launch ? Customers’ communication ? Product Innovation ? Responsible marketing ? Satisfaction survey and complaint channels ? Cooperation and communication ? Information security ? Official WeChat account ? Product quality and safety Suppliers and partners ? Protection of human rights ? Supply chain management ? Empowerment and training ? Industry activities ? Responsible procurement ? Anti-corruption ? Working conferences ? Online or offline regular communication Employee ? Employees' rights and interests ? Talent attraction and retention ? Employee symposiums ? Employee training ? Occupational health and safety ? Diversity & equal opportunities ? Meetings of employee ? Employees' complaint and ? Employee development and ? Protection of human rights representatives reporting mechanism training ? Labor union ? Culture discussion platform ? Balance between work and life Environment and communities ? Community investment ? Energy and resource conservation ? Charity projects and ? Regular communication with ? Low-carbon technologies ? Responsible purchasing fundraising platforms media ? Waste management ? Green office ? Information disclosure ? Joining social organizations? Water management ? Climate change ? Media-related conferences? Emission management ? Access to health care Double Materiality Analysis Based on the double materiality principle and the requirements of the Guidelines No. 14 of the Shanghai Stock Exchange for Self-Regulation of Listed Companies—Sustainability Reporting (Trial), Haier Biomedical has systematically identified and assessed the ESG issues related to its business operations. We conducted a comprehensive analysis of the impacts of our business activities on the external environment and society (hereinafter referred to as "impact materiality"), as well as the potential effects of relevant issues on the Company's financial performance, business model, and costs (hereinafter referred to as "financial materiality").Through the above analysis process, we identified a total of 29 material issues this year, three of which are financially material. Based on the assessment results, we developed the materiality matrix below to support the Company in further identifying key sustainability management priorities and formulating action plans. For the identified financially material issues, we have disclosed them in the relevant sections of this report in alignment with the four dimensions of "Governance – Strategy – Impact, Risk and Opportunity Management – Metrics and Targets". Double Materiality Assessment Process Double Materiality Matrix Practices ESG management practices. Haier Biomedical and SDGs Pillar UN SDGs Strategic Focus of Haier Biomedical Progress of Haier Biomedical in 2025 Innovation-Led Adhere to innovation-led development and Defined the "create a world-class brand in the life sciences that is trusted globally" strategic direction as strive to be a technical leader in the life the fundamental driving force of technological innovation. Implemented this through domestic "Three science and medical innovation fields and Expansions and Two Focuses" and overseas "Country-by-country Strategy" market strategies. industry. Expanded the openness pattern and integrated internal and external resources through four forms—Empower global public health through self-developed, co- research, mergers and acquisitions, and incubation—to build a diversified and innovative achievements and serve national complementary R&D ecosystem. Deeply integrated artificial intelligence into product R&D and launched strategies. a series of "AI+" solutions. Drive industry progress and collaborate Completed the R&D and launch of over 70 new models based on core platforms such as ultra-low with multiple parties to achieve co-creation temperature storage, automation, cell culture, and centrifugation. and win-win results. Accumulated 1,620 authorized patents and 428 software copyrights.Integrity and Build a solid bottom line for compliant Continuously refined the corporate governance and risk management system to solidify the foundation Shared Success operations and create a stable, high-quality for stable development.corporate governance level. Strengthened the construction of a business ethics culture and conducted business ethics and anti-Remember product responsibility and corruption training and promotional activities for all employees to enhance compliance and legal solidify the foundation of product safety awareness and create a clean business environment.and quality to provide trustworthy products Formulated the Medical Technology Ethics and Governance Policy to adhere to technological ethical and services for customers and the industry. guidelines and codes of conduct in R&D activities such as scientific research, technological development, and application. Required all suppliers to sign the Supplier Code of Conduct, clarifying requirements for quality control, integrity, green procurement, human rights protection, and conflict mineral management to drive upstream and downstream enterprises in the supply chain to practice green development concepts.Established a comprehensive product quality management system to support the "zero defect" goal by clarifying responsibilities, strictly controlling processes, and scientifically setting standards.Obtained the EU Medical Device Regulation (MDR) certification and the South Korean KGMP certification to further expand global market access. Guided by the "zero complaint" service goal, continuously deepened the construction of the customer Total number of employees and carbon-reduction actions throughout The number of newly with non-storage- Anti-corruption education sessions for middle granted invention related invention and senior managers the entire lifecycle. 2,945 patents increased by patents accounting for 2 year-over-year 50 % 73 % Average training hours per employee Integrity and self-discipline awareness 2.367 million kWh training coverage 36.29 hours A total of software copyrights have 100 % of employees campus 428 been obtained Employee training percentage accounting for 100% A total of Supplier integrity agreement signing rate technical achievements have been 18.18 % 34 recognized as reaching the 100 % international leading level of the Company’s total electricity consumptionRMB 1.406 million Achieved annual target of Accumulated Invested and provincial-level or higher science and 10 % defect rate 51 technology awards RMB 257,700 2,139 hours in environmental in environmental work-related injuries protection funds protection initiatives Quality training sessions Cumulatively led or participated in the formulation of 0 11 national, industry, and group standards Customer On-time customer satisfaction rate service response rate 0.70 0.18 Haier Biomedical is committed to building a more resilient and We are building a new global ecosystem of shared growth and sustainable global health ecosystem through technological innovation technology empowerment. Anchored in localized services with global and localization. Against the backdrop of evolving global public coverage, driven by innovative scenario-based solutions, supported by health needs and infrastructure upgrades in emerging markets, Haier superior technological products, and committed to low-carbon and Biomedical's internationalization has evolved from single-product energy-saving contributions, we are developing scalable, trustworthy, sales to delivering comprehensive solutions centered on "product + and affordable health technology infrastructure and public health service". Driven by technological innovation, anchored in localized systems. This initiative aims to promote the efficient allocation of services, and oriented toward sustainable operations, the Company medical resources and the inclusive extension of services. The proportion of The number of newly A total of Accumulated 0.70 R&D personnel added invention 428 51 reached patents increased by valid patents per RMB software copyrights provincial-level or higher science million revenue% % 28.56 50 have been obtained and technology awards year-over-year SDG-related responses in this Section Total R&D investment with non-storage A total of Cumulatively led or participated 0.18 invention patents in the formulation of amounted to 1.1 R&D and Innovation Against the backdrop of rapid technological iteration in the life sciences sector and a reshaping R&D innovation is the key pathway for Haier Biomedical to build long-term competitiveness. of the global industrial landscape, Haier Biomedical leverages technological innovation as its By optimizing our organizational structure and operating the "Four Horizontal and Four fundamental driving force. The Company has clearly defined its strategic direction to "create a Vertical" technology platform while building an open R&D ecosystem, we continuously world-class brand in the life sciences that is trusted globally" and is advancing implementation enhance innovation efficiency to provide solid support for capturing market trends and through market strategies such as domestic "Three Expansions and Two Focuses" and overseas achieving high-quality development. "country-by-country strategy". At the same time, we focus on three product development directions:1.1.1 Governance in multiple technologies, including variable-capacity refrigeration unit and the 10W high-Digital & Digital & Digital & Intelligent R&D Technology R&D Management Mode of Haier Biomedical R&D Management System Tianjin Haier Biomedical Tianjin R&D Center upgraded and built the "Four Horizontal and Four Vertical" UAE Global User Experience CentreUK Global Marketing Centre foundation for growth. In terms of R&D layout, Haier Biomedical further expanded Haier Biomedical has established a robust laboratory testing system to provide solid hardware and standards support for its global R&D network during the reporting period by research, development, and innovation. The Company’s testing center has established more than 30 specialized laboratories establishing R&D centers in Tianjin and Guangzhou, covering areas such as overall product performance, reliability, environmental adaptability, safety, and user experience. building upon its existing coverage across 9 provinces and The testing center has obtained accredited testing capabilities recognized by the China National Accreditation Service for municipalities in China as well as overseas networks in the Conformity Assessment (CNAS), covering 65 domestic and international standards and 609 testing items, thereby establishing United States, the United Kingdom, and the United Arab comprehensive international inspection and testing capabilities across multiple dimensions, including software, hardware, Emirates. These initiatives have effectively strengthened the scenarios, and applications. At the same time, the testing center has established a rapid prototyping line for new products, Laboratory of Haier Biomedical In terms of R&D team building, Haier Biomedical continues As of the end of the to cultivate internal talent and actively recruit external talent, Haier Biomedical Laboratory has obtained four categories of international certifications, including RMB million 323 the first UL Client Test Data Program (CTDP) laboratory qualification in China's industry, as well as Total R&D investment Haier Biomedical adheres to the philosophy of openness and TüV Rheinland Witness Laboratory accreditation, and CNAS laboratory recognition.collaboration, continuously building and deepening an innovation accounted for cooperation ecosystem with universities, research institutions, During the reporting period, we continued to expand our During the product development process, we have embedded 1.1.4 Metrics and Targets industry-academia-research cooperation network by initiating risk management into each stage, establishing a normalized project collaborations with multiple universities, including mechanism: To evaluate the effectiveness of R&D innovation, Haier Biomedical Xi'an Jiaotong University, Huazhong University of Science and has established quantitative targets for indicators such as Technology, and Beihang University, as well as institutions invention patent applications, new product development R&D Risk Management Process such as the Guangzhou National Laboratory. Concurrently, completion rates, and the proportion of revenue from new product R&D in the interdisciplinary field of medicine and to discuss key topics and Metrics Targets Progress in 2025 Training of high-value patents. Simultaneously, it established a patent 1,620 70Compliance Management risk monitoring system to prevent infringement risks, thereby System Certificate The total number of The number of invention patents newly strengthening its capabilities in the creation, protection, and patents granted granted in 2025 utilization of intellectual property. The number of Haier Biomedical’s patents and software copyrightsIntellectual Property Management Initiatives 210 1,083 327 428 Optimize Patent Quality and Incentives Establish a patent intelligence analysis The total number of The total number of The total number The total number of and monitoring system invention patents utility model patents of design patents software copyrights granted granted granted granted ? Establish Patent Review Board (PRB), ? Establish a patent monitoring Performance Highlights in this Section Percentage of Anti-corruption Supplier integrity Quality female directors education sessions agreement training for middle and signing rate sessions 33.3% senior managers 100% 11 2 SDGs-related responses in this Section Percentage of Integrity and self- Achieved annual Customer On-time customer female senior discipline awareness target of satisfaction rate service response rate Nomination safeguard long-term and sustainable development. Committee Committee Appraisal Committee Committee 2.1.1 Corporate Governance Haier Biomedical has always valued the independence of the Board of Directors. During Haier Biomedical has established a corporate governance system with a clear structure and the reporting period, we updated the Working System for Independent Directors to provide well-defined roles and responsibilities, laying a solid foundation for the Company's scientific institutional support for the performance of their duties. As of the end of the reporting decision-making and long-term development. We continuously optimize Board independence period, the Company had three independent directors on the Board, accounting for 33.3% and diversity, improve information disclosure and investor relations management, enhance of the Board. The independent directors, in compliance with relevant regulations, attended governance effectiveness, and ensure the Company's compliant and stable operations.Board meetings, shareholders' meetings, special committee meetings, and independent director meetings. They fully utilized their professional knowledge to put forward reasonable Board Operations suggestions and opinions, thus promoting the efficient operation and scientific decision-making of the Board. Haier Biomedical strictly abides by the Company Law of the People's Republic of China, During the reporting period, Haier Biomedical actively organized specialized governance the Securities Law of the People's Republic of China, the Code of Corporate Governance for training for its directors, senior management, and personnel in key positions across various Listed Companies, the STAR Market Listing Rules of the Shanghai Stock Exchange and any departments. The training covered topics such as independent director workshops, market other relevant laws and regulations. We continuously improve our corporate governance value management, and ESG compliance, continuously enhancing their ability to fulfill their structure, enhance Board diversity, and ensure the Company's compliant operations and duties in compliance with listed company governance requirements.value creation. During the reporting period, Haier Biomedical held 2 Shareholders' meetings, 6 Board Haier Biomedical has established a governance structure consisting of the Shareholders' meetings, 3 independent director special meetings, 8 special committee meetings, and 1 Meeting, the Board of Directors, its specialized committees and management. All members employee representative meeting. These meetings covered matters such as regular reports, of the Board of Directors are elected by the Shareholders' Meeting. The Board of Directors profit distribution, related-party transactions, the abolition of the Board of Supervisors, the oversees the Company's affairs and makes operational decisions on behalf of the Company, election of an employee representative director, equity incentives, and the revision of the and has the right to appoint and remove the Company's senior management and make major Company's Articles of Association and other systems. decisions regarding the Company’s day-to-day operations. Haier Biomedical always values Board diversity as a key factor in achieving the Company's During the reporting period, in accordance with relevant regulatory requirements, Haier sustainable development. When selecting Board members, we take into account multiple Biomedical abolished the Board of Supervisors and transferred its duties to the Audit Committee, dimensions, including gender, age, cultural and educational background, professional which assumed the responsibility for supervising the conduct of the Company's directors qualifications, as well as industry and work experience, to ensure the fairness and objectivity of and senior management. In addition, the Company elected Mr. Liu Zhanjie as the employee the Board's decision-making and create long-term value for the Company and its stakeholders. representative director on the third session of the Board of Directors, further optimizing the As of the end of the reporting period, the Company had three female directors on the Board, Board's composition and enhancing the Company's level of standardized governance.accounting for 33.3% of the Board. List of Board Members and Diverse Backgrounds Investor Communication Haier Biomedical strictly abides by the regulatory requirements of the Administrative Position Name Gender Educational Background Measures for Information Disclosure by Listed Companies and the Working Guidelines for Chairman Tan Lixia Female Doctor of Advanced Professional Studies in Applied the Relationship between Listed Companies and Investors, and has formulated the Haier Finance Biomedical Investor Relations Management System. The Company continuously improves the quality and transparency of its information disclosure, strengthens communication with Director Zhou Yunjie Male Ph.D. in Business Administration investors, and promotes investors' understanding and recognition of the Company. Director Liu Zhanjie Male Ph.D. in Refrigeration and Cryogenic Engineering We ensure timely and transparent information disclosure through multiple channels, such Master of Business Administration as holding performance briefings and Investor Day events, the SSE e-Interaction platform, investor hotlines, and dedicated investor relations columns, continuously enhancing investor Director Gong Wenwen Female Bachelor of Management and Economics trust. During the reporting period, we published 27 investor relations records, responded to 107 inquiries on the SSE e-Interaction platform, held 4 earnings briefings and regional investor Director Chen Jie Female Master of Business Administration events, engaged with nearly 100 investor visits, published 27 investor relations articles on our Bachelor of Applied Chemistry with a Specialization official WeChat public account, and fielded hundreds of calls on our investor hotline. in Ceramics The Company places great emphasis on delivering returns to its shareholders and diligently Director Hu Xiangde Male Bachelor of Economics protects their legitimate rights and interests. Since its listing, we have implemented a dividend policy for six consecutive years, with cumulative dividends amounting to RMB 788 Independent Huang Sheng Male PhD in Economics, Washington University (St. Louis) million. In 2025, the Company launched its third share buyback plan, with a total repurchase Director Master of Economics, University of Cambridge value of RMB 100 million. Double Bachelor in History and Economics, Peking During the reporting period, Haier Biomedical actively 2.1.2 Risk Management applied digital intelligence technologies and newly Haier Biomedical strictly abides by relevant laws and regulations, and has developed internal risk management policies such established the AI Sentinel risk prevention system, which as the Comprehensive Risk Management System Operating Standards and the Major Operational Risk Incident Reporting and now covers 86 key risk indicators across 7 core business Handling Standards. These policies standardize risk management processes, strengthen risk control capabilities, and safeguard scenarios. The system sets dynamic thresholds based on the Company's stable operations. historical data and industry benchmarks, and automatically identifies anomalies through AI models, triggering a three- We have established a risk management framework with clearly defined roles and responsibilities, as well as collaborative level (red, yellow, orange) early warning mechanism. This coordination. The Board of Directors, Audit Committee, management, internal control team, and external audit institutions each enables early detection and intervention of risks, effectively perform their respective functions within the risk prevention and control system, ensuring timely and effective risk prevention enhancing the accuracy of risk identification and the and response. efficiency of risk control. Haier Biomedical has established the Wanlian three-tier risk management system and the three-level internal control During the reporting period, we conducted a total of 7 management system, clearly defining three risk categories: field, operation, and execution. Corresponding internal control special and routine audits, and worked collaboratively with management strategies have been formulated for managers at different levels (field, industry platform, and chain group), relevant business units to address issues such as process ensuring that the internal control management system covers the smallest business units, all business types, and all operating gaps identified during these audits. At the same time, we regions. During the reporting period, the Company carried out a comprehensive risk assessment project with reference to the continuously strengthened the verification and follow-up COSO Enterprise Risk Management Framework and the Wanlian field three-tier risk management framework, identified over 27 of remediation measures to ensure the adaptability and risk points, and defined prevention and control entities and strategies for each type of identified risk point. effectiveness of our risk management measures. Furthermore, the Company strengthened its Three-Check System (self-inspection, mutual inspection, and specialized |
